drugset
drugset / Trial / NCT04952545

Study of ALXN2050 in Healthy Adult Participants of Japanese Descent

NCT04952545 ↗

Phase 1 Completed 20 enrolled Alexion Pharmaceuticals, Inc.
RandomizedParallel-groupDouble-blindBasic science

Summary

This is a Phase 1 bridging study being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALXN2050 after both single- and multiple-dosing in healthy participants of Japanese descent.

Timeline

Start
2021-07-09
Primary completion
2021-09-07
Completion
2021-09-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Vemircopan Small molecule 120 mg Oral
Subject Vemircopan Small molecule 180 mg Oral

Indications

No indication recorded.